Hong Kong stock market moves differently | CanSino Biologics (06185.HK) rose more than 3% as its inhaled tuberculosis vaccine clinical trial receives approval from the Indonesian drug regulatory authority.

According to the Wisdom Financial APP, Kangxinuo Biology (06185.HK) has risen by more than 3%, as of the time of publication, it has risen by 2.7%, reaching 32.35 Hong Kong dollars, with a trading volume of 6.8385 million Hong Kong dollars.